Recruiting

Spinal & General Anesthesia

Sponsor:

Rhode Island Hospital

Code:

NCT07316166

Conditions

Postoperative Pain Management

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Dexmedetomidine

Ropivacaine

Study Details

Brief summary:

The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.

Conditions

Postoperative Pain Management

Study ID

NCT07316166

Start date

Jan 20, 2026

Status verified date

Mar, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients undergoing elective total hip arthroplasty
  • 18-80 years old
  • ASA 1-3 classifications

Exclusion Criteria:

  • ASA classification of 4 or greater
  • Infection at the site of nerve blockade
  • Coagulopathy
  • Known allergy to study medications
  • Chronic opioid consumption (>3 months)
  • Currently using lidocaine patches
  • Pre-existing neuropathy
  • A history of CVA
  • High grade atrioventricular block (cardiac conduction system impairment)
  • Organ dysfunction (cardiac failure, respiratory failure, end stage renal disease, hepatic dysfunction, hypoalbuminemia)
  • Morbid obesity (≥40 kg/m2)
  • Prior surgery in supra and/or infrainguinal region
  • Non-English-speaking participants

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

active comparator: Ropivacaine

30 ml of 0.25% ropivacaine; No dexmedetomidine

experimental: Ropivacaine plus Dexmedetomidine

30 ml of 0.25% ropivacaine; 1 mcg/kg of dexmedetomidine

Interventions

Dexmedetomidine

Participants in the experimental arm receive a preoperative suprainguinal fascia iliaca block consisting of 30 mL of 0.25% ropivacaine combined with perineural dexmedetomidine at a dose of 1 mcg/kg.

Ropivacaine

In the experimental arm, ropivacaine (30 mL of 0.25%) is administered with dexmedetomidine.

In the active comparator arm, ropivacaine (30 mL of 0.25%) is administered alone without any dexmedetomidine medication.

Primary outcome measure

  • Time of administration of first analgesic after the surgery [ Time Frame: Time to first analgesic request, defined as the interval (in minutes) from block administration to the first request for rescue analgesia, assessed for up to 24 hours. ]

Central Contacts and Locations

Central contacts

Vendhan Ramanujam, M.D.

401-444-5172vramanujam@brownhealth.org

Locations

The Miriam Hospital

Recruiting

Providence, Rhode Island, United States, 02906

Contacts

Renee Dupre

401-793-4575rdupre@brownhealth.org

Mark Kendall, M.D.

401-444-4722mark.kendall@brownhealth.org

More Information

Sponsor

Rhode Island Hospital

Last update posted

Mar 25, 2026

Last verified

Mar, 2026

Keywords

  • Hip Surgery
  • Nerve block

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Rhode Island Hospital on 2026-03-25.